肿瘤标志物在结直肠癌诊疗应用中的研究进展  

Advances in the Research of the Application of Tumor Markers in the Diagnosis and Treatment of Colorectal Cancer

作　　者：邹璐泽 齐秋晨 李培龙 李娟[1] 王传新 杜鲁涛[2] ZOU Luze;QI Qiuchen;LI Peilong;LI Juan;WANG Chuanxin;DU Lutao(Department of Clinical Laboratory,The Second Hospital Shandong University,Jinan 250033;Department of Clinical Laboratory,Qilu Hospital,Shandong University,Shandong Provincial Key Laboratory of Laboratory Medicine Innovation Technology,Jinan 250012,China)

机构地区：[1]山东大学第二医院检验医学中心,济南250033 [2]山东大学齐鲁医院检验医学中心,山东省检验医学创新技术重点实验室,济南250012

出　　处：《中国细胞生物学学报》2023年第12期1783-1792,共10页Chinese Journal of Cell Biology

基　　金：山东省重点研发计划(批准号:2021ZLGX02)资助的课题。

摘　　要：结直肠癌(colorectal cancer,CRC)是世界第三大常见恶性肿瘤,也是全球癌症相关死亡的主要原因之一。近年来,随着各种新兴组学测序技术和人工智能的发展,肿瘤标志物在临床肿瘤学中的应用研究不断拓宽。以DNA甲基化、非编码RNA、循环肿瘤细胞、肠道菌群及代谢物为主的新型标志物逐渐成为肿瘤诊疗研究中的重点方向,在CRC的早筛早诊、病情监测及预后评估等方面起着重要的指导作用。该文就近年来临床常用肿瘤标志物和新型肿瘤标志物在CRC诊疗中的应用及进展进行了综述,并对检验大数据和人工智能在肿瘤临床诊疗中的潜在应用前景进行了讨论,以期为CRC的诊疗应用研究提供借鉴。CRC(colorectal cancer)is the third most common malignancy and one of the leading causes of cancer-related deaths worldwide.In recent years,with the development of various emerging omics sequencing technologies and artificial intelligence,the application of tumor markers in clinical oncology has been expanding.Novel biomarkers based on DNA methylation,non-coding RNA,circulating tumor cells,gastrointestinal microbiome and metabolites have gradually become the key directions in cancer diagnosis and treatment research,and play an important guiding role in the early screening and diagnosis of CRC,efficacy testing and prognosis evaluation.This article reviews the application and progress of commonly used CRC tumor biomarkers and new tumor biomarkers in the diagnosis and treatment of CRC,and discusses the potential application prospects of big data and artificial intelligence in the diagnosis and treatment of tumors,in order to provide a reference for the research on the diagnosis and treatment of CRC.

关 键 词：结直肠癌 肿瘤标志物 早期诊断 预后预测 

分 类 号：R735.34[医药卫生—肿瘤]